These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 28719500

  • 1. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B.
    Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
    [Abstract] [Full Text] [Related]

  • 2. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M, Zambrano B, Santos-Lima E.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [Abstract] [Full Text] [Related]

  • 3. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
    Aquino AG, Brito MG, Doniz CE, Herrera JF, Macias M, Zambrano B, Plennevaux E, Santos-Lima E.
    Vaccine; 2012 Oct 05; 30(45):6492-500. PubMed ID: 22863658
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
    Prymula R, Kieninger D, Feroldi E, Jordanov E, B'Chir S, DaCosta X.
    Pediatr Infect Dis J; 2018 Aug 05; 37(8):823-830. PubMed ID: 29762363
    [Abstract] [Full Text] [Related]

  • 5. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
    Vesikari T, Borrow R, Da Costa X, Richard P, Eymin C, Boisnard F, Lockhart S.
    Vaccine; 2017 Jan 11; 35(3):452-458. PubMed ID: 27939054
    [Abstract] [Full Text] [Related]

  • 6. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E.
    Pediatr Infect Dis J; 2013 Aug 11; 32(8):889-97. PubMed ID: 23538523
    [Abstract] [Full Text] [Related]

  • 7. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration.
    Madhi SA, López P, Zambrano B, Jordanov E, B'Chir S, Noriega F, Feroldi E.
    Hum Vaccin Immunother; 2019 Aug 11; 15(3):658-668. PubMed ID: 30513252
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.
    Martinón-Torres F, Diez-Domingo J, Feroldi E, Jordanov E, B'Chir S, Da Costa X.
    Pediatr Infect Dis J; 2019 Mar 11; 38(3):317-322. PubMed ID: 30408001
    [Abstract] [Full Text] [Related]

  • 9. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T, Borrow R, Da Costa X, Thomas S, Eymin C, Boisnard F, Lockhart S.
    Vaccine; 2018 Dec 18; 36(52):8019-8027. PubMed ID: 30471953
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2019 Dec 18; 15(4):809-821. PubMed ID: 30444673
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R, Kotloff K, Hoffenbach A, San Martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM.
    Pediatr Infect Dis J; 1998 Apr 18; 17(4):294-304. PubMed ID: 9576383
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
    Tapiéro B, Halperin SA, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee AW, Li M, Tomovici A.
    Pediatr Infect Dis J; 2013 Jan 03; 32(1):54-61. PubMed ID: 23241989
    [Abstract] [Full Text] [Related]

  • 17. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
    Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2012 May 03; 43(3):687-98. PubMed ID: 23077849
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.
    Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E.
    Int J Infect Dis; 2011 Apr 03; 15(4):e249-56. PubMed ID: 21334243
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.